Core Insights - The experimental animal industry in China is undergoing a transformation, focusing on animal welfare and the development of specialized products for experimental animals [1][2] - The industry is moving towards self-research and development of animal welfare products, establishing a complete industrial chain from breeding to drug testing [1] Group 1: Industry Transformation - The experimental animal industry is evolving to prioritize animal welfare, with products like toys and comfort items being developed to reduce stress and anxiety in animals [1] - The market for animal comfort products is significant, with estimates exceeding 100 million yuan, indicating a growing demand for such items [1] Group 2: Technological Advancements - The company, 集萃药康, is utilizing advanced technologies such as CRISPR/Cas9 for gene modification and AI for creating virtual mice to enhance research capabilities [2] - The company has developed around 30,000 strains of experimental mice, positioning itself among the global leaders in this field [2] Group 3: Research and Development Focus - The focus on animal welfare is seen as essential for obtaining reliable experimental data, emphasizing the importance of healthy and well-cared-for animals in research [1][2] - The company is also exploring cutting-edge fields such as organ-on-a-chip and brain-machine interfaces, indicating a commitment to innovation in biomedical research [2]

Core Viewpoint - The announcement from Shengnuo Biotech indicates a change in the partnership structure of a significant shareholder, which has resulted in a decrease in the combined shareholding percentage of the actual controller and their concerted parties, but does not affect the overall control of the company [1] Group 1 - The execution partner of Hainan Shengnuo Enterprise Management Center (Limited Partnership) has changed, leading to the termination of the concerted action relationship with its concerted parties [1] - The combined shareholding percentage of the actual controller, Mr. Wen Yongjun, and his concerted parties has decreased from 33.77% to 30.82%, reaching a 1% threshold [1] - There is no change in the number of shares held, and the respective shareholding quantities and proportions remain unchanged [1] Group 2 - The termination of the concerted action relationship will not lead to a change in the company's controlling shareholder or actual controller [1]

证券代码：688117 证券简称：圣诺生物 公告编号：2025-028 成都圣诺生物科技股份有限公司 成都圣诺生物科技股份有限公司（以下简称"公司"）于近日收到圣诺管理 出具的《关于海南圣诺企业管理中心（有限合伙）执行事务合伙人变更的告知函》， 经圣诺管理全体合伙人一致同意，圣诺管理执行事务合伙人由文永均先生变更为 余啸海先生。近日圣诺管理已经完成执行事务合伙人变更（以下简称"本次变更"） 的工商登记备案手续，并取得了海南省市场监督管理局换发的《营业执照》。 关于股东解除一致行动关系暨权益变动触及 1%刻度 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次权益变动是因公司股东海南圣诺企业管理中心（有限合伙）（以 下简称"圣诺管理"）的执行事务合伙人发生变更，与其一致行动人解除一 致行动关系所致，不涉及股东持股数量变动，各自的持股数量和持股比例保 持不变。 本次一致行动关系解除不会导致公司控股股东、实际控制人发生变 化。 上述变更后，圣诺管理与公司实际控制人文永均先生、马兰文女士及其控制 的 ...

Core Viewpoint - Chengdu Saintno Biological Technology Co., Ltd. anticipates significant growth in net profit for the first three quarters of 2025, with projections indicating an increase of 100.53% to 145.10% compared to the same period last year [1][3]. Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 114.20 million yuan and 139.57 million yuan for the first three quarters of 2025, representing an increase of 57.25 million yuan to 82.63 million yuan year-on-year [1]. - The projected net profit, after deducting non-recurring gains and losses, is estimated to be between 113.35 million yuan and 138.54 million yuan, reflecting an increase of 59.70 million yuan to 84.89 million yuan year-on-year [1]. Previous Year Performance - In the same period last year, the net profit attributable to shareholders of the parent company was 56.95 million yuan, and the net profit after deducting non-recurring gains and losses was 53.66 million yuan [2]. Reasons for Performance Change - The company's main business has shown stable development, with a continuous increase in demand for its peptide raw material business, contributing to a steady rise in overall performance and maintaining strong market competitiveness and profitability [3].

Group 1: Company Announcements - Hezhong Intelligent (合锻智能) reported no revenue from nuclear fusion-related business [1] - Fostar (福斯达) plans to invest approximately 1 billion yuan in the construction of a marine engineering and equipment intelligent manufacturing project [1] - Zhongyan Dadi (中岩大地) won a contract for a 770 million yuan engineering project [1] - Meili Technology (美力科技) intends to acquire 10.1% equity in Beijing Dayuan and Jiangsu Dayuan [1] - Jiuan Medical (九安医疗) plans to repurchase shares worth 300 million to 600 million yuan [1] - Sanmei Co., Ltd. (三美股份) expects a net profit increase of 171.73% to 193.46% year-on-year for the first three quarters [1] - Chen Yategong (陈亚特工) plans to reduce holdings by 2.99% [1] - Asia-Pacific Pharmaceutical (亚太药业) intends to raise no more than 700 million yuan through a private placement to Xinghao Holdings [1] - Feiliwa (非利华) plans to raise no more than 300 million yuan through a private placement [2] Group 2: Investment Projects - New Asia Cable (新亚电缆) plans to invest 298 million yuan in a green and environmentally friendly cable industry project [1] - Fostar (福斯达) is set to invest about 1 billion yuan in a marine engineering and equipment intelligent manufacturing project [1] Group 3: Share Buybacks - China Merchants Industry Holdings (中远海控) plans to repurchase 50 million to 100 million A-shares [2] - Jiuan Medical (九安医疗) intends to repurchase shares worth 300 million to 600 million yuan [2] - China National Machinery Industry Corporation (中工国际) plans to repurchase shares worth 50 million to 100 million yuan [2] - Fujilai (富士莱) plans to repurchase shares worth 20 million to 40 million yuan [2] - Obizhongguang (奥比中光) plans to repurchase shares worth 25 million to 50 million yuan [2] Group 4: Performance Forecasts - Sanmei Co., Ltd. (三美股份) expects a net profit increase of 171.73% to 193.46% year-on-year for the first three quarters [2] - Yuegui Co., Ltd. (粤桂股份) anticipates a net profit increase of 86.87% to 109.11% year-on-year for the first three quarters [2] - Salt Lake Co., Ltd. (盐湖股份) expects a net profit increase of 36.89% to 49.62% year-on-year for the first three quarters [2] - Shengnuo Biotechnology (圣诺生物) anticipates a net profit increase of 100.53% to 145.1% year-on-year for the first three quarters [2] Group 5: Equity Transfers - Yonghe Zhikong (永和智控) plans to transfer 51% equity and debt of Taixing Puluo [1] - Meizhi Co., Ltd. (美芝股份) plans to transfer 51% equity of Yingju Construction [1] - Meili Technology (美力科技) intends to acquire 10.1% equity in Beijing Dayuan and Jiangsu Dayuan [1] - Kangwei Century (康为世纪) plans to acquire 49% equity of its subsidiary Haowei Tai [1]

Core Viewpoint - Shengnuo Bio announced a voluntary disclosure of its performance forecast for the first three quarters of 2025, expecting a significant increase in net profit compared to the same period last year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company between 114.20 million and 139.57 million yuan for the first three quarters of 2025 [1] - This represents an increase of 57.25 million to 82.63 million yuan compared to the same period last year, reflecting a year-on-year growth of 100.53% to 145.10% [1]

Group 1: Financial Performance - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 45% to 65% due to reforms and improved investment returns [2] - Feirongda anticipates a net profit of 275 million to 300 million yuan for the first three quarters of 2025, reflecting a growth of 110.80% to 129.96% driven by increased R&D in AI and cooling technologies [2] - Lingyi Zhizao forecasts a net profit of 1.890 billion to 2.120 billion yuan for the first three quarters of 2025, marking a growth of 34.10% to 50.42% attributed to new product launches and increased overseas revenue [5] - Yilake Co. expects a net profit of 4.300 billion to 4.700 billion yuan for the first three quarters of 2025, with a significant increase of 36.89% to 49.62% driven by rising potassium chloride prices [6] - Bojun Technology projects a net profit increase of 50% to 80% for the first three quarters of 2025 [9] Group 2: Regulatory and Corporate Actions - Fudan Zhangjiang's application for the drug Obeticholic Acid for primary biliary cholangitis was not approved by the National Medical Products Administration, with a total R&D investment of approximately 125 million yuan [3] - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau for failing to disclose non-operating fund occupation by an affiliate, totaling 8.9485 million yuan [7] - Tianji Co. announced that its major shareholders reduced their holdings by 2.9996% and have terminated their reduction plan ahead of schedule [8] Group 3: Market Trends and Developments - The demand for AI server cooling solutions and related materials has increased, contributing to Feirongda's revenue growth [2] - The overall market for potassium chloride has seen price increases, positively impacting Yilake Co.'s profitability [6] - The consumer electronics market is recovering, leading to increased demand for thermal management materials, benefiting Feirongda's market share [2]

Core Viewpoint - Shengnuo Biotech (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit between 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.1% [1] Financial Performance - The company anticipates a net profit increase of 57.25 million to 82.63 million yuan compared to the same period last year [1] - The projected net profit for the first three quarters is between 114 million to 140 million yuan [1] Business Development - Shengnuo Biotech reports stable development in its main business, with continuous growth in demand for its peptide raw materials business [1] - The ongoing construction of production capacity is contributing to the sustained growth in orders, which in turn is driving overall performance improvement [1] - The company maintains strong market competitiveness and continuous profitability [1]

Company Announcements - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau due to undisclosed non-operating fund occupation by related parties, amounting to 8.9485 million yuan, which has been fully repaid [2] - Aosheng Electronics reported that revenue from controllable nuclear fusion-related products will account for less than 1% of its main business revenue in the first half of 2025 [2] - Yiyi Co. is planning to acquire a pet food company, leading to a stock suspension [3] - Sanmei Co. expects a net profit increase of 172%-193% year-on-year for the first three quarters, driven by a significant rise in the average price of fluorinated refrigerants [4] - Feirongda anticipates a net profit increase of 111%-130% year-on-year for the first three quarters, with growth in AI server cooling-related business revenue [4] - Zhongshi Technology expects a net profit increase of 74%-104% year-on-year for the first three quarters, benefiting from increased shipments of thermal materials and components [4] - Juxin Technology forecasts a net profit increase of 113% year-on-year for the first three quarters, with sales revenue from edge AI processor chips increasing significantly [4] - Chuangjiang New Materials expects a staggering net profit increase of 2058%-2243% year-on-year for the first three quarters [4] - New China Life Insurance anticipates a net profit increase of 45%-65% year-on-year for the first three quarters [4] Investment & Contracts - Fostda plans to invest 1 billion yuan in the construction of an intelligent manufacturing project for marine engineering and equipment [11] Shareholding Changes - Dongxin Co. has set an initial transfer price of 82.5 yuan per share for its inquiry transfer, which is a 16% discount from the closing price [11] - China Jushi has obtained a commitment letter for a stock repurchase loan of up to 630 million yuan [12] - Tianji Co. has reduced its holdings by 2.9996% of the company's shares and has terminated its reduction plan early [3] Performance & Operations - Yingweike reported a net profit of 183 million yuan for the third quarter, an increase of 8.35% year-on-year [13] - Chenguang Biological expects a net profit increase of 344%-402% year-on-year for the first three quarters [14] - Meili Ecology's subsidiary won a bid for a 2.375 billion yuan urban renewal project in Shenzhen [18] Stock Price Movements - Hezhu Intelligent has not generated any revenue related to nuclear fusion concepts [19] - Jinli Yongci confirmed that its recent stock price fluctuations are not due to undisclosed significant matters [20] Other Developments - Heng Rui Medicine's subsidiary received approval for clinical trials of SHR-1905 injection [24] - Renfu Medicine received a drug registration certificate for Dapoxetine Hydrochloride Tablets, which are expected to generate approximately 1.1 billion yuan in sales in 2024 [26]

Core Viewpoint - Shengnuo Bio (688117.SH) expects a significant increase in net profit for the first three quarters of 2025, projecting a range of 114 million to 140 million yuan, representing a year-on-year increase of 57.25 million to 82.63 million yuan, or 100.53% to 145.10% [1] Group 1 - The company's main business is experiencing stable development, contributing to overall performance growth [1] - The demand for orders in the peptide raw material business is continuously increasing due to the ongoing capacity expansion [1] - The substantial growth in performance allows the company to maintain strong market competitiveness and sustained profitability [1]